- 2017 American Transplant Congress - Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.Chronic antibody-mediated rejection due to anti-human leukocyte antigen (HLA) antibodies (Abs) is an important problem in organ transplantation. The spleen has been reported to be…
- 2017 American Transplant Congress - Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.- Yale University, New Haven, CT Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…
- 2017 American Transplant Congress - Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…
- 2017 American Transplant Congress - C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.Background: In a previous study we searched the association between the flow cytometry cross-match assay (FXM) result and the results obtained in the analysis of…
- 2017 American Transplant Congress - Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…
- 2016 American Transplant Congress - A Virtual Crossmatch Algorithm That Mimics the Sensitivity of Flow Cytometric Crossmatch.- NJ Sharing Network, New Providence, NJ. Aim: The new Kidney Allocation System has increased requests for virtual crossmatches (VXM) to predict the possibility of a negative donor specific crossmatch. This study…
- 2016 American Transplant Congress - Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).- 1Houston Methodist Hospital, Houston, TX; 2Kansas University Medical Center, Kansas City, KS. Intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
- 2016 American Transplant Congress - Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
- 2016 American Transplant Congress - Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.- 1Nephrology, CHP, Porto, Portugal; 2CSTP, Porto, Portugal. HLA-incompatible kidney transplantation is associated with worse outcomes given the presence of donor-specific anti-HLA antibodies (DSA). Our aim was to investigate the association between preformed…
- 2016 American Transplant Congress - Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 47
- Next Page »
